Healwell AI (TSX: AIDX) Revenue Run Rate About to Rise From $20M up to $65M+

NIA has said since day one when it first announced Healwell AI (TSX: AIDX) on February 28th at $0.93 per share as its #1 favorite healthcare AI stock suggestion that AIDX Chairman Hamed Shahbazi = the Elon Musk of AI. People thought we were exaggerating, but we were being truthful. Anybody who is paying attention right now is seeing it first-hand. No other executive of any AI company on this planet is executing like he is.

One week ago, NIA sent out an alert entitled: 'Healthcare AI Revolution Is Underway'.

NIA said in its alert, "AIDX has rapidly established a revenue run-rate of $20 million and has a strong and active acquisition and business development pipeline in place with the potential to more than double its revenue run-rate to over $40 million using only the cash on hand that they had prior to its recent equity raise of $20 million. Including the $20 million of additional capital that AIDX now has, there is no telling how many additional new healthcare AI businesses that AIDX is likely to rapidly roll up in the upcoming months."

On Tuesday, AIDX announced the acquisition of healthcare AI company VeroSource.

On Thursday, AIDX announced the acquisition of healthcare AI company BioPharma Services Inc.

After the closing of both acquisitions, AIDX will have a revenue run rate of more than $65 million!

Instead of doubling its revenue run rate from $20 million up to $40 million like Hamed Shahbazi promised, AIDX's revenue run rate is about to instantly increase at least 3.25X higher to $65 million!

On top of that AIDX has signed a partnership with Takeda (TAK) a US$42 BILLION market cap company! AIDX and TAK will use AIDX's Pentavere and its best-in-class AI engine DARWEN to drive real-world evidence analysis for rare diseases, particularly focusing on supporting patients suffering from hereditary angioedema (HAE) with normal C1 inhibitor, which is an ultra-rare disease characterized by life-threatening recurrent, unpredictable swelling, and currently does not have any approved treatments!

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA has received compensation from AIDX of US$50,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.